In an open-label extension of the phase 3 DRAGON trial, 456 Asian adults with chronic migraine received erenumab 70 mg monthly (median 79.9 weeks): 71.9% had an adverse event, 15.1% treatment-related (mainly constipation, 7.5%); 2.9% stopped due to adverse events.
RCTn = 456
Yu et al. Long-term safety and continued clinical benefit of erenumab 70 mg in Asian patients with chronic migraine: an open-label extension of the phase 3 DRAGON study